Champigny Sur Marne

This research aims to compare two methods of early screening to identify infants at risk for Autism Spectrum Disorder and Neurodevelopmental Disorders. It targets infants under 12 months of age to provide early access to care, hoping to improve outcomes by detecting developmental delays compared to typical age expectations. The study is conducted at multiple Maternal and Child Protection Services in France and follows infants up to 48 months of age. Two screening approaches are evaluated during routine visits for vaccinations or developmental exams at 4 and 9 months. One method involves a health professional assessing neurodevelopment through routine observations of motor skills, vocalizations, babbling, and social interactions. The other method uses the PREAUT grid, a specific screening tool for autism spectrum disorders. Infants showing abnormal results are referred promptly to specialized centers for further advice and treatment when needed. Participants will have follow-ups at 12, 24, and 36 months including developmental assessments like the Modified Checklist for Autism in Toddlers and the Child Development Inventory. Additional diagnostic tools are used if initial tests indicate concerns. The study also collects data on treatments received, parental psychological state, quality of life, and family impact. Health insurance data will track care pathways up to 48 months. The main outcome is the proportion of children diagnosed and receiving care before age one.

Researchers are evaluating two anesthesia approaches for patients undergoing hand surgery, focusing on reducing anxiety during the operation. This study compares the effects of adding neuroleptanalgesia or hypnoanalgesia to locoregional anesthesia. The main goal is to measure changes in anxiety levels before and after surgery using a visual scale. Secondary goals include comparing pain, surgery duration, hospital stay, sedative use, patient satisfaction, and side effects between the groups. Participants receive locoregional anesthesia by a trunk block and are randomly assigned to one of two groups. One group receives neuroleptanalgesic treatment with Hypnovel dosed by weight, while the other group undergoes hypnoanalgesia sessions led by a trained nurse using hypnosis techniques tailored to each patient. These treatments are administered during outpatient hand surgeries such as flexor tenosynovectomy or carpal tunnel release. During the study, participants will be assessed for anxiety and pain levels before, during, and after surgery, along with satisfaction and safety monitoring. The main outcome is the anxiety score on day 2 after surgery. Researchers will also track procedure duration, intensive care and hospital stay, additional sedative use, and any adverse events. Participation involves signing consent and attending scheduled evaluations until day 2 post-surgery.

Researchers are conducting a French non-interventional longitudinal multicenter cohort study to evaluate the added value of olaparib for treating patients with metastatic castration-resistant prostate cancer mCRPC in real-world settings. The study aims to assess treatment sequencing, effectiveness, safety, and BRCA testing patterns, helping to inform future clinical practice. This observational study is sponsored by AstraZeneca. The study observes adult male patients who have started olaparib treatment within at least the last two months or who participated in a funded early access program. There are no assigned treatment groups or interventions beyond olaparib use as decided by their physician. Data collection continues up to 32 months to capture treatment patterns and patient characteristics. Participants data on treatment duration, disease progression, therapy sequences, symptomatic skeletal events, and BRCA testing timing will be collected and analyzed up to 24 months from olaparib initiation. Socio-demographic and clinical characteristics of patients and physicians will be gathered at the end of enrollment. The study monitors reasons for dose changes, interruptions, and treatment cessation, ensuring comprehensive real-world evidence about olaparib in mCRPC patients.

This research aims to observe patients in France with HER2-negative early breast cancer who are treated with olaparib, a medication chosen by their doctors. The study focuses on understanding how often patients complete the full course of olaparib treatment and gathers information on related genetic factors and medical history. It is a national, multicenter, prospective observational study without experimental treatment assignment. Participants in this study receive adjuvant olaparib treatment as part of their usual care under their physicians discretion. The study does not assign treatments but follows patients who start olaparib, tracking their treatment progress for up to 18 months after inclusion. There are no additional interventions or placebo groups. Throughout the study, researchers collect data on treatment completion rates, types of BRCA mutations, variant types, medical history, and the time until olaparib treatment stops. Participation involves observational follow-up, with no extra treatment visits beyond routine care. The overall participation lasts 18 months after a patients enrollment, focusing on real-world treatment experiences and outcomes.